The pregnancy outcome of progestin‐primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial

Abstract

An RCT confirmed similar pregnancy outcome in P-primed ovarian stimulation with a daily dose of 4 or 10 mg MPA.

Progestin‐primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing in vitro fertilization/intracytoplasmic sperm injection: A prospective randomized controlled trial

“…The sample size was based on the primary outcome (the proportion of women with profound pituitary suppression). In our preliminary trial, this proportion was 32% in the PPOS protocol, and the calculated sample size was 134 when this percentage was reduced by half (16%). Given the possibility of dropouts, the sample size required for this randomized trial was 160.…”

“…We performed a binary logistic regression analysis to determine the association between variables involved in profound pituitary suppression (Table S1). A serum LH concentration <1.0 IU/L on the trigger day was set as the cut‐off for profound pituitary suppression . The percentage of women with profound pituitary suppression was significantly lower in the study group than in the control group (1.9% [3/160] vs 33.1% [53/160], P < .001).…”

“…The primary outcome measure for this study was the percentage of women with profound pituitary suppression characterized by a LH concentration <1.0 IU/L on the trigger day . The secondary outcomes were the endocrinological profiles, incidence of a premature LH surge, duration and dosage of hMG, number of oocytes and viable embryos retrieved, clinical pregnancy outcomes from FET cycles and implantation rate.…”

“…The PPOS protocol is promising due to its many advantages, including oral administration, reduced frequency of hormonal monitoring and reduced risk of OHSS . The continuous supply of progestin during PPOS can lead to strong pituitary suppression, and nearly one‐third of women experience profound pituitary suppression . Additionally, the requirement for a higher dose of Gn in the PPOS protocol than in the short protocol might be related to the extent of pituitary suppression .…”

Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?

“…Studies available in the literature so far, involving more than 2600 patients (Begueria et al, 2019;Chen et al, 2017;Dong et al, 2017;Kuang et al, 2015;Wang et al, 2016b;Yu et al,2018;Zhu et al, 2015Zhu et al, , 2017aZhu et al, , 2017b, are summarized in TABLE 2. The first study on the use of a progestin during ovarian stimulation was published by colleagues in 2015 (Kuang et al, 2015).…”